Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
National Research ( (NRC) ) just unveiled an update.
On August 25, 2025, National Research Corporation announced the appointment of Shane Harrison as Executive Vice President and Chief Financial Officer, effective September 25, 2025. Harrison, with over 25 years of experience in finance and strategic transactions, is expected to drive NRC Health’s growth and profitability. His compensation package includes a base salary, signing bonus, and restricted shares, with vesting conditions tied to his continued employment and potential change in control scenarios.
The most recent analyst rating on (NRC) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on National Research stock, see the NRC Stock Forecast page.
Spark’s Take on NRC Stock
According to Spark, TipRanks’ AI Analyst, NRC is a Outperform.
National Research’s overall stock score reflects solid technical momentum and a fair valuation, despite financial performance challenges. The company’s profitability and cash generation are strong, but high leverage and declining revenue growth are concerns. The stock’s technical indicators suggest positive momentum, while the valuation remains attractive with a reasonable P/E ratio and a solid dividend yield.
To see Spark’s full report on NRC stock, click here.
More about National Research
NRC Health is a publicly-traded company specializing in healthcare experience. For over 40 years, it has focused on humanizing healthcare by supporting organizations in understanding each individual through a patient-focused approach, market research, and consumer preferences, thereby transforming the healthcare experience.
Average Trading Volume: 99,713
Technical Sentiment Signal: Sell
Current Market Cap: $354.7M
For an in-depth examination of NRC stock, go to TipRanks’ Overview page.